Active, Not Recruiting
A Study of Efficacy and Safety of Pembrolizumab Plus Enfortumab Vedotin (EV) +/- Investigational Agents in First-Line Metastatic Urothelial Carcinoma (mUC) (MK-3475-04B/KEYMAKER-U04)
NCT05845814
- Conditions
- Carcinoma, Carcinoma, Transitional Cell, Metastatic Urothelial Carcinoma, +4 more
- Locations
-
- Moores Cancer Center ( Site 3028) La Jolla, California, United States
- University of California, Irvine (UCI) Health - UC Irvine Medical Center ( Site 3045) Orange, California, United States
- UCSF Medical Center at Mission Bay ( Site 3044) San Francisco, California, United States
- Anschutz Cancer Pavilion ( Site 3017) Aurora, Colorado, United States